Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 66NET 40CNS 9Gastrointestinal 7Thoracic 5Head & Neck 4Genitourinary 4Dermatologic 3Sarcoma 1Gynecologic 1

Conditions

Sarcoma 960Glioblastoma 299Gliosarcoma 288Osteosarcoma 286Brain Neoplasms 195Dendritic Cell Sarcoma, Interdigitating 188Gastrointestinal Stromal Tumors 180Bone Neoplasms 172Lymphoma 161Central Nervous System Neoplasms 160Astrocytoma 155Sarcoma, Ewing 151Glioma 149Precursor Cell Lymphoblastic Leukemia-Lymphoma 147Lymphoma, Non-Hodgkin 143Burkitt Lymphoma 139Neoplasms 137Recurrence 134Lymphoma, Large B-Cell, Diffuse 128Lymphoma, Follicular 128Rhabdomyosarcoma 126Neuroblastoma 126Hodgkin Disease 124Oligodendroglioma 123Breast Neoplasms 123Lymphoma, Mantle-Cell 117Leukemia, Myeloid, Acute 117Leukemia, Lymphocytic, Chronic, B-Cell 117Lymphoma, B-Cell, Marginal Zone 113Leukemia 111

Interventions

Dacarbazine 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoid Tumor × Sarcoma × Clear all
NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Virginia Commonwealth University

Phase 1 Completed
17 enrolled
DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡